Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France. One of two late-breaking oral presentations will feature results from Cohort K of EV-103 (also known as KEYNOTE-869), a phase 1b/2 clinical trial conducted in partnership with Astellas. Cohort K is evaluating PADCEV® (enfortumab vedotin-ejfv) as monotherapy or in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy. Merck is known as MSD outside the United States and Canada.
A second late-breaking oral presentation will include additional results from the phase 2 MOUNTAINEER trial evaluating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). Patient-reported outcomes from MOUNTAINEER also will be detailed in a separate presentation. Data from the MOUNTAINEER trial formed the basis of a supplemental New Drug Application submitted to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Program. On July 28, 2022, the FDA granted Breakthrough Therapy Designation for tucatinib in combination with trastuzumab for the treatment of adult patients with unresectable or metastatic HER2-positive CRC who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy. The designation is based on results from the MOUNTAINEER trial.
“These important data to be shared at the ESMO Congress reflect our commitment to develop innovative solutions for patients with challenging clinical needs in cancer,” said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development at Seagen.
Presentations of Company-Sponsored Trials
|
ABSTRACT TITLE |
PRESENTATION # |
PRESENTATION TYPE |
LEAD AUTHOR |
|
PADCEV® (enfortumab vedotin-ejfv) |
|||
|
Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) |
LBA73 |
Oral Presentation / Proffered Paper Session 2: GU Tumours, Non-prostate, September 12, 14:55-15:05 CEST |
J. Rosenberg |
|
TUKYSA® (tucatinib) |
|||
|
Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC |
LBA27 |
Mini Oral Presentation / Mini Oral Session: GI, Lower Digestive, September 12, 14:50-14:55 CEST |
J. H. Strickler |
|
Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER |
361P |
Poster Session 7, September 11, 12:00-13:00 CEST |
C. Wu |
|
TUKYSA® (tucatinib) Trials in Progress |
|||
|
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress) |
438TiP |
Poster Session 8, September 11, 12:00-13:00 CEST |
T. André |
|
Disitamab vedotin Trials in Progress |
|||
|
Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001, trial in progress) |
1779TiP |
Poster Session 12, September 12, 12:00-13:00 CEST |
V. S. Koshkin |
|
Health Economics and Outcomes Research |
|||
|
Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes |
376P |
Poster Session 8, September 11, 12:00-13:00 CEST |
T. S. Bekaii-Saab |
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of PADCEV, TUKYSA, disitamab vedotin and the company’s other products and product candidates, including their potential efficacy, safety and therapeutic uses, and the potential for TUKYSA to receive accelerated approval from the FDA based on data from the MOUNTAINEER trial. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that data from the MOUNTAINEER trial and other trials may not be sufficient to support any regulatory approvals; the risk of adverse events, including the potential for newly-emerging safety signals; adverse regulatory actions; delays, setbacks or failures in clinical development activities, the submission of regulatory applications and the regulatory review process for a variety of reasons, including the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the year ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005258/en/
Contact information
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Douglas Maffei, Ph.D.
(425) 527-4881
dmaffei@seagen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces HEVC Advance and VVC Advance Pricing through 203022.7.2025 03:00:00 EEST | Press release
Access Advance LLC (“Advance”) today announced the results of several significant decisions by the Licensors in both the HEVC Advance and VVC Advance Patent Pools. Both patent pools opted to maintain their current royalty rates and caps for Licensees who sign before December 31, 2025, and to extend an incentive that aligns the royalty caps for Advance’s Multi-Codec Bridging Agreement (“MCBA”) and the VVC Advance Patent Pool for Licensees who sign the MCBA during the same period. The result is that Licensees who join the HEVC Advance program, gaining access to more than 27,000 patents, on or before December 31, 2025, can lock in current rates and caps through 2030. This protection applies both to ongoing royalty obligations and calculation of royalties due for past sales. Additionally, both current and new HEVC Advance Licensees who join the VVC Advance Patent Pool and execute the MCBA by December 31, 2025, will enjoy MCBA royalty caps that match the royalty caps for the VVC Advance pro
MayMaan Launches Engine Integration Program to Accelerate Clean Combustion Deployment and Market Adoption21.7.2025 20:34:00 EEST | Press release
MayMaan, a scale-up innovator, transforming combustion technology, is announcing a robust and scalable partnership model to support the transition to more efficient power systems across global industries whilst cutting harmful emissions such as NOx and SOx to levels that are practically immeasurable. At the heart of MayMaan’s offering is its proprietary AquaStroke® technology, which runs on a revolutionary 70% water and 30% ethanol fuel blend. This patented system delivers high torque and reliability while dramatically reducing emissions—offering a compelling alternative to diesel engines and electrification overhauls. “Our technology is more than a breakthrough—it’s a platform designed to help others succeed,” said Doron Shmueli, Founder and CEO at MayMaan. “From manufacturers to distributors, we provide a full solution—ready to integrate, easy to scale, and built for the energy demands of tomorrow.” Tailored Solutions for Industry Leaders MayMaan’s clean combustion platform is now av
Armis Named a Leader in Unified Vulnerability Management Solutions, Q3 2025 Evaluation21.7.2025 18:25:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest score in the Current Offering category. According to the report, “Armis’ strategy is grounded in proactive security principles… Armis is an excellent fit for either beginner organizations starting their proactive security journey or mature organizations that need leading vulnerability response capabilities.” “I believe Armis stood out as a Leader because Armis CentrixTM is different – it’s a platform built to help organizations reduce cyber risk, not just report on it,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We are redefining what security should look like in a connected world, helping organizations move from passive defense to proactive control so that they can take action before there’s any impact on their environment.
DevvStream Completes $10M Initial Funding to Launch $300M Asset-Backed Digital Infrastructure and Sustainability Strategy21.7.2025 18:00:00 EEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced that it has entered into a securities purchase agreement for the issuance of up to (US)$300 million in senior secured convertible notes (“Senior Notes”), advancing its strategic initiative to build a blockchain-based treasury and launch a tokenization platform for sustainability-linked infrastructure. The securities purchase agreement provides for the issuance of up to (US)$300 million in Senior Notes with Helena Partners, which issuances will be funded in multiple tranches. An initial funding of (US)$10 million was completed on July 18, 2025. Key Highlights: Under the agreement, DevvStream will allocate 75% of the net proceeds (70% of the initial tranche) toward the purchase of liquid digital assets that offer 24/7 liquidity, serve as non-correlated stores of value, and may be used as collateral
McCauley Propeller Systems High-Performance C780 Propeller Now Factory Standard for New Beechcraft King Air 360 Customers21.7.2025 16:00:00 EEST | Press release
McCauley Propeller Systems, a division of Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced its C780 propeller, which had previously been optional for factory installation, is now standard for all new commercial customers of the Beechcraft King Air 360. The first King Air 360 equipped with the propeller recently rolled out of production at Textron Aviation’s factory in Wichita, Kansas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250720080635/en/ McCauley Propeller Systems high-performance C780 propeller now factory standard for new Beechcraft King Air 360 customers (Photo Credit: McCauley Propeller Systems) "As a leading full-line propeller manufacturer, being featured on the factory line of the legendary Beechcraft King Air 360 underscores our commitment to excellence," said Jason Hull, vice president and general manager, McCauley Propeller Systems. “The C780 offers a sophisticated and durable de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom